Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,463,116

« Back to Dashboard

Summary for Patent: 5,463,116

Title: Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
Abstract:Stable crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine may be produced by treating this compound with a solvent at a temperature of at least 10.degree. C. and forming crystals in the solvent at a temperature of at least 10.degree. C. For example, crystals may be formed by crystallization out of solution, or may be formed from solid particles of the compound suspended in a solvent. Crystals formed in this way have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms of the compound and have enhanced processability, e.g., stability to grinding.
Inventor(s): Sumikawa; Michito (Kawasaki, JP), Koguchi; Yoshihito (Kawasaki, JP), Ohgane; Takao (Kawasaki, JP), Irie; Yasuo (Kawasaki, JP), Takahashi; Satoji (Yottukaichi, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:08/190,460
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,463,116

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan3-189696Jul 30, 1991
Japan3-199453Aug 08, 1991

International Patent Family for Patent: 5,463,116

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0526171<disabled in preview>01C0044France<disabled>
European Patent Office0526171<disabled in preview>31/2001Austria<disabled>
European Patent Office0526171<disabled in preview>C300063Netherlands<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.